Navigation Links
Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

PRINCETON, N.J., Jan. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 29th Annual J.P. Morgan Healthcare Conference to be held January 10-13, 2011 at the Westin St. Francis Hotel, San Francisco, CA. Schaefer Price, President and Chief Executive Officer, will provide an overview of the company on Wednesday, January 12, 2011 at 9:00 AM (PT).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in tw
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced it received ... H, a hemp-based, advanced headache relief product, for planned ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Group (MRG), the global authority on medical technology ... research data for multiple geographies, including the US, ... MRG,s peripheral vascular reports cover minimally invasive ... stenting, percutaneous transluminal balloon angioplasty, and synthetic surgical ...
... RO, ROG; OTCQX: RHHBY) and study investigators from Harvard ... the PROTECT ( Pr o-BNP O utpatient ... T herapy) trial, a strategy of NT-proBNP guided heart ... in total cardiovascular events, the primary composite endpoint of ...
Cached Medicine Technology:New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events 2NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events 3
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of ... developmental biology, and research for metabolic and genetic disorders. ... widely used techniques for the discovery and development of ... is rapidly growing worldwide. In 2012, there were 14.1 ... 32.6 million people living with cancer (within five years ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... are more common in women than in men, says Coping ... School. Scientists are// examining hormonal and biological factors, as well ... ,Women are twice as likely to suffer from ... are three times as likely to have agoraphobia (fear of ...
... by retina surgeons at The Methodist Hospital shows unprecedented ... treated with Lucentis? for wet// age-related macular degeneration (AMD), ... Journal of Medicine. AMD is a major cause of ... causes of blindness in people over 60. ...
... toll from the mosquito-borne virus has risen to six in ... died of the disease in the paediatric ward of King ... the Farrukhabad district hospital,' V.S. Nigam, health department spokesman told ... cases has shot up to 199 in the state with ...
... that behavioral therapies can benefit children who have problems falling ... ,The American Academy of Sleep Medicine (AASM) appointed a team ... and toddlers. ,According to study author Jodi A. ... shown 20 to 30 percent of young children have sleep ...
... Pradesh villager suffering from a serious kidney ailment died ... premier hospital here//, apparently because he could not afford ... of a window of the nephrology ward of the ... he was being treated, hospital sources told IANS. ...
... debate on the issue of organ donation. The author advocates ... will help in meeting the excessive demand for transplants and ... is an organ transplant surgeon by profession has opined that ... requirement for organs whilst remaining on the right side of ...
Cached Medicine News:Health News:Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements 2
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
Steroid eluting pacemaker leads...
Medicine Products: